financetom
Business
financetom
/
Business
/
IHS Swings to Q1 Loss, Revenue Falls; Shares Decline Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IHS Swings to Q1 Loss, Revenue Falls; Shares Decline Pre-Bell
May 14, 2024 6:30 AM

09:06 AM EDT, 05/14/2024 (MT Newswires) -- IHS Holding ( IHS ) reported a Q1 loss Tuesday of $4.67 per diluted share, swinging from earnings of $0.03 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.04.

Revenue for the quarter ended March 31 was $417.7 million, down from $602.5 million a year earlier.

Four analysts surveyed by Capital IQ expected $394.0 million.

The company maintained its full-year 2024 revenue guidance of $1.70 billion to $1.73 billion. Analysts surveyed by Capital IQ expect $1.73 billion.

Shares of the telecommunications tower company fell 3.4% in recent Tuesday premarket activity.

Price: 3.7200, Change: -0.13, Percent Change: -3.38

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SolarEdge Technologies to Exit Energy Storage, Cut 500 Jobs
SolarEdge Technologies to Exit Energy Storage, Cut 500 Jobs
Nov 27, 2024
07:54 AM EST, 11/27/2024 (MT Newswires) -- SolarEdge Technologies ( SEDG ) said Wednesday it will shut down its energy storage division and lay off about 500 employees, mostly in South Korea, as part of its strategy to focus on core solar activities. The company said it expects to save $7.5 million in quarterly operating expenses due to the closure...
CervoMed Says it Gets FDA's Orphan Drug Designation for Neflamapimod to Treat Frontotemporal Dementia
CervoMed Says it Gets FDA's Orphan Drug Designation for Neflamapimod to Treat Frontotemporal Dementia
Nov 27, 2024
07:53 AM EST, 11/27/2024 (MT Newswires) -- CervoMed ( CRVO ) said Wednesday it has received orphan drug designation for its investigational drug neflamapimod from the US Food and Drug Administration to treat frontotemporal dementia. Neflamapimod was generally well tolerated in phase 1 and phase 2 clinical studies, the company said, adding that it intends to start a phase 3...
enCore Energy Transitions to US Domestic Filer, Names KPMG as Auditor
enCore Energy Transitions to US Domestic Filer, Names KPMG as Auditor
Nov 27, 2024
07:54 AM EST, 11/27/2024 (MT Newswires) -- enCore Energy (EU) said Wednesday that it will change its reporting status with the US Securities and Exchange Commission from a foreign filer to a domestic US filer, effective Jan. 1. The company said that in support of the transition, it has appointed KPMG as its new auditor, replacing Davidson. ...
Camtek Gets Over $50 Million in Initial Orders for New Hawk Product
Camtek Gets Over $50 Million in Initial Orders for New Hawk Product
Nov 27, 2024
07:53 AM EST, 11/27/2024 (MT Newswires) -- Camtek ( CAMT ) said Wednesday it obtained initial orders exceeding $50 million for its Hawk platform from multiple customers, with deliveries slated for 2025. The Hawk, targeting advanced packaging technologies like 3D wafer inspection and Hybrid Bonding, expands Camtek's ( CAMT ) market reach and will be launched at Semicon Korea in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved